Telesta Therapeutics Inc  

(Public, TSE:TST)   Watch this stock  
Find more results for TSE:BNC
-0.005 (-3.57%)
Sep 23 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.14 - 0.14
52 week 0.04 - 1.00
Open 0.14
Vol / Avg. 0.00/3.19M
Mkt cap 39.45M
P/E 82.32
Div/yield     -
EPS 0.00
Shares 303.07M
Beta -0.33
Inst. own     -

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets 5.83% -52.13%
Return on average equity 8.13% -
Employees 53 -
CDP Score - -


2600 Alfred-Nobel Blvd Suite 301
+1-514-6976636 (Phone)
+1-514-6977966 (Fax)

Website links


Telesta Therapeutics Inc., formerly Bioniche Life Sciences Inc., is a Canada-based biopharmaceutical company. The Company is focused on the development, manufacturing, commercialization and licensing/acquisition of therapies for the global health market. The Company has developed the Mycobacterium phlei Cell Wall-Nucleic Acid Complex (MCNA) technology, a biologic immunotherapy or immunomodulator for the treatment of bladder cancer patients with high-risk non-muscle invasive bladder cancer who failed prior bacillus Calmette-Guerin (BCG) therapy. MCNA is a cell wall-nucleic acid composition prepared from the fractionation of a pure culture of Mycobacterium phlei. The Company has completed Phase III clinical trials for its MCNA product candidate. It is engaged in preparing for the commercial launch of MCNA in the United States. The Company's MCNA manufacturing site is located in Pointe Claire, Quebec. The Company has not generated any revenues from its operations.

Officers and directors

James M. Rae Independent Chairman of the Board
Michael Joseph Berendt Ph.D. Chief Executive Officer, Chief Scientific Officer
Age: 67
Brian R. Ford Chief Financial Officer
Age: 67
Donald Olds Chief Operating Officer
Mohamed Elrafih Vice President - Manufacturing Operations
Yvon Bastien Independent Director
Age: 67
Lyne Fortin Independent Director
Gregory David Gubitz Independent Director